CA2374133A1 - Structural models for cytoplasmic domains of transmembrane receptors - Google Patents

Structural models for cytoplasmic domains of transmembrane receptors Download PDF

Info

Publication number
CA2374133A1
CA2374133A1 CA002374133A CA2374133A CA2374133A1 CA 2374133 A1 CA2374133 A1 CA 2374133A1 CA 002374133 A CA002374133 A CA 002374133A CA 2374133 A CA2374133 A CA 2374133A CA 2374133 A1 CA2374133 A1 CA 2374133A1
Authority
CA
Canada
Prior art keywords
paxillin
integrin
polypeptide
cytoplasmic domain
heptad
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002374133A
Other languages
English (en)
French (fr)
Inventor
Martin Pfaff
Shouchun Liu
Mark H. Ginsberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2374133A1 publication Critical patent/CA2374133A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/7055—Integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
CA002374133A 1999-06-01 2000-06-01 Structural models for cytoplasmic domains of transmembrane receptors Abandoned CA2374133A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32344799A 1999-06-01 1999-06-01
US09/323,447 1999-06-01
PCT/US2000/015153 WO2000073342A1 (en) 1999-06-01 2000-06-01 Structural models for cytoplasmic domains of transmembrane receptors

Publications (1)

Publication Number Publication Date
CA2374133A1 true CA2374133A1 (en) 2000-12-07

Family

ID=23259240

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002374133A Abandoned CA2374133A1 (en) 1999-06-01 2000-06-01 Structural models for cytoplasmic domains of transmembrane receptors

Country Status (5)

Country Link
EP (1) EP1180122A4 (ja)
JP (1) JP2003504308A (ja)
AU (1) AU765990B2 (ja)
CA (1) CA2374133A1 (ja)
WO (1) WO2000073342A1 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006112738A1 (en) * 2005-04-19 2006-10-26 Auckland Uniservices Limited Novel peptides and methods for the treatment of inflammatory disorders
WO2008061563A1 (de) * 2006-11-22 2008-05-29 Aplagen Gmbh Peptide für die behandlung der multiplen sklerose

Also Published As

Publication number Publication date
WO2000073342A1 (en) 2000-12-07
JP2003504308A (ja) 2003-02-04
AU765990B2 (en) 2003-10-09
EP1180122A1 (en) 2002-02-20
AU5177300A (en) 2000-12-18
EP1180122A4 (en) 2003-03-26

Similar Documents

Publication Publication Date Title
Kishore et al. Modular organization of the carboxyl-terminal, globular head region of human C1q A, B, and C chains
Schwarzbauer Identification of the fibronectin sequences required for assembly of a fibrillar matrix.
Simonds et al. Receptor and effector interactions of Gs Functional studies with antibodies to the αs carboxyl‐terminal decapeptide
JP3560344B2 (ja) プロトカドヘリンタンパク質およびその使用
Moroianu et al. Mammalian karyopherin alpha 1 beta and alpha 2 beta heterodimers: alpha 1 or alpha 2 subunit binds nuclear localization signal and beta subunit interacts with peptide repeat-containing nucleoporins.
Ahmad et al. Assembly of gap junction channels: mechanism, effects of calmodulin antagonists and identification of connexin oligomerization determinants
Chuang et al. Molecular cloning, expression, and mapping of the high affinity actin-capping domain of chicken cardiac tensin.
JPH05502228A (ja) インテグリン―リガンド結合を阻害するペプチドおよび抗体
EP0636174B1 (en) Hyaluronan receptor (rhamm = receptor for hyluronan mediated mobility) and hyaluronan binding peptides
CA2324381C (en) An integrin heterodimer and a subunit thereof
US20030113828A1 (en) Compositions and methods for modulating Syk function
Bennasroune et al. Inhibition by transmembrane peptides of chimeric insulin receptors
Kashiwagi et al. Affinity modulation of platelet integrin ɑIIbß3 by ß3-endonexin, a selective binding partner of the ß3 integrin cytoplasmic tail
US6303317B1 (en) Peptide probes and methods for making the same
EP0804728A1 (en) Assay, receptor proteins and ligands
Andersen et al. Annexin-V binds to the intracellular part of the β5 integrin receptor subunit
WO1998032848A9 (en) Peptide probes to coil proteins and methods for making the same
US6846908B2 (en) DCR-5 bone affecting ligand
AU765990B2 (en) Structural models for cytoplasmic domains of transmembrane receptors
EP1200588B1 (en) Single-chain polypeptides comprising troponin i n-terminal fragments and troponin c
AU755574B2 (en) Synthetic peptide immunogens and antibodies thereto
Kalinin et al. Breaking the connection: caspase 6 disconnects intermediate filament-binding domain of periplakin from its actin-binding N-terminal region
US20020198360A1 (en) Structural models for cytoplasmic domains of transmembrane receptors
SK170497A3 (en) Cytoplasmic modulators of integrin regulation/signaling
EP0835319A1 (en) INTERACTION OF p53 WITH TRANSCRIPTION FACTOR DP-1

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead